Drug Search Results
More Filters [+]

Otlertuzumab

Alternative Names: otlertuzumab, tru-016, tru016, tru 016
Latest Update: 2021-05-20
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CD37 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Aptevo
Company Location: SEATTLE WA 98121
Company CEO: Marvin White
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Otlertuzumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma

Phase 1: Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|T-Cell Leukemia|T-Cell Peripheral Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01644253

P1

Terminated

Lymphocytic Chronic B-Cell Leukemia|T-Cell Peripheral Lymphoma|Chronic Lymphoid Leukemia|T-Cell Leukemia|Lymphoma, B-Cell

2020-02-24

28%

2010-019554-41

P2

Completed

Chronic Lymphoid Leukemia

2014-12-11

NCT01188681

P2

Completed

Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia

2014-12-01

NCT01317901

P1

Completed

Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell

2013-04-01

Recent News Events

Date

Type

Title